Novo Nordisk: The New PayPal?

James FoordInvesting Group LeaderFollow5ShareSavePlay(6min)Comments(4)SummaryNovo Nordisk faces renewed pressure after CagriSema failed to match Eli Lilly’s tirzepatide in a key Phase 3 trial.Despite margin compression and weak 2026 guidance, NVO remains a cash-generative leader in the expanding obesity market.Even under bearish scenarios, downside risk appears limited, with robust free cash flow and high gross margins supporting valuation.NVO's current valuation offers an attractive entry point for long-term investors anticipating eventual sentiment recovery.This idea was discussed in more depth with members of my private investing community, The Pragmatic Investor. Learn More » Henrik Sorensen/DigitalVision via Getty Images Thesis Summary Just when you think Novo Nordisk A/S (NVO) can't go any lower, it gets some more bad news, and the stock dips further. The stock already collapsed in 2025 as GLP-1 enthusiasm faded and political pressure intensified. Now, justThis article was written byJames Foord27.16K FollowersFollowJames Foord is an economist by trade and has been analyzing global markets for the past decade. He leads the investing group The Pragmatic Investor where the focus is on building robust and truly diversified portfolios that will continually preserve and increase wealth.

The Pragmatic Investor covers global macro, international equities, commodities, tech and cryptocurrencies and is designed to guide investors of all levels in their journey. Features include a The Pragmatic Investor Portfolio, weekly market update newsletter, actionable trades, technical analysis, and a chat room. Learn more.Analyst’s Disclosure: I/we have a beneficial long position in the shares of NVO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.